References
- Bont L, Checchia PA, Fauroux B, et al. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in western countries. Infect Dis Ther. 2016;5(3):271–298. doi:https://doi.org/10.1007/s40121-016-0123-0.
- Miller EK, Gebretsadik T, Carroll KN, et al. Viral etiologies of infant bronchiolitis, croup and upper respiratory illness during 4 consecutive years. Pediatr Infect Dis J. 2013;32(9):950–955. doi:https://doi.org/10.1097/INF.0b013e31829b7e43.
- Meissner HC. Viral bronchiolitis in children. N Engl J Med. 2016;374(1):62–72. doi:https://doi.org/10.1056/NEJMra1413456.
- Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588–598. doi:https://doi.org/10.1056/NEJMoa0804877.
- McNamara PS, Flanagan BF, Selby AM, et al. Pro- and anti-inflammatory responses in respiratory syncytial virus bronchiolitis. Eur Respir J. 2004;23(1):106–112. doi:https://doi.org/10.1183/09031936.03.00048103.
- Moreno-Solís G, Torres-Borrego J, de la Torre-Aguilar MJ, et al. Analysis of the local and systemic inflammatory response in hospitalized infants with respiratory syncitial virus bronchiolitis. Allergol Immunopathol (Madr). 2015;43(3):264–271. doi:https://doi.org/10.1016/j.aller.2014.02.002.
- Ruckwardt TJ, Morabito KM, Graham BS. Determinants of early life immune responses to RSV infection. Curr Opin Virol. 2016;16:151–157. doi:https://doi.org/10.1016/j.coviro.2016.01.003.
- Baddley JW, Cantini F, Goletti D, et al. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents). Clin Microbiol Infect. 2018;24:S10–S20. doi:https://doi.org/10.1016/j.cmi.2017.12.025.
- Schlüter D, Deckert M. The divergent role of tumor necrosis factor receptors in infectious diseases. Microbes Infect. 2000;2(10):1285–1292. doi:https://doi.org/10.1016/S1286-4579(00)01282-X.
- Lendak DF, Mihajlović DM, Novakov-Mikić AS, et al. The role of TNF-α superfamily members in immunopathogenesis of sepsis. Cytokine. 2018;111:125–130. doi:https://doi.org/10.1016/j.cyto.2018.08.015.
- Jovanovic M, Gajovic N, Zdravkovic N, et al. Fecal galectin-3: a new promising biomarker for severity and progression of colorectal carcinoma. Mediators Inflamm. 2018;2018:8031328. doi:https://doi.org/10.1155/2018/8031328.
- Sushama S, Dixit N, Gautam RK, et al. Cytokine profile (IL-2, IL-6, IL-17, IL-22, and TNF-α) in vitiligo - new insight into pathogenesis of disease. J Cosmet Dermatol. 2019;18(1):337–341. doi:https://doi.org/10.1111/jocd.12517.
- Diaz PV, Gaggero AA, Pinto RA, et al. Levels of inflammatory cytokines and plasma cortisol in respiratory syncytial virus bronchiolitis. Rev Med Chil. 2013;141:574–581. doi:https://doi.org/10.4067/s0034-98872013000500004.
- Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–e34. doi:https://doi.org/10.1016/j.jclinepi.2009.06.006.
- National Heart Lung and Blood Institute. Study Quality Assessment Tools. United States: National Institutes of Health. 2018:1–35.
- Larrañaga CL, Ampuero SL, Luchsinger VF, et al. Impaired immune response in severe human lower tract respiratory infection by respiratory syncytial virus. Pediatr Infect Dis J. 2009;28(10):867–873. doi:https://doi.org/10.1097/INF.0b013e3181a3ea71.
- Mella C, Suarez-Arrabal MC, Lopez S, et al. Innate immune dysfunction is associated with enhanced disease severity in infants with severe respiratory syncytial virus bronchiolitis. JID. 2013;207(4):564–573. doi:https://doi.org/10.1093/infdis/jis721.
- Pinto RA, Arredondo SM, Bono MR, et al. T helper 1/T helper 2 cytokine imbalance in respiratory syncytial virus infection is associated with increased endogenous plasma cortisol. Pediatrics. 2006;117(5):e878–e886. doi:https://doi.org/10.1542/peds.2005-2119.
- Tabarani CM, Bonville CA, Suryadevara M, et al. Novel inflammatory markers, clinical risk factors and virus type associated with severe respiratory syncytial virus infection. Pediatr Infect Dis J. 2013;32(12):e437–e442. doi:https://doi.org/10.1097/INF.0b013e3182a14407.de.
- Welliver TP, Garofalo RP, Hosakote Y, et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. 2007;195:1126–1136. doi:https://doi.org/10.1086/512615.
- Yuan X, Li Y, Shen Y, et al. Clinical and Th1/Th2 immune response features of hospitalized children with human rhinovirus infection. J Med Virol. 2020;92(1):26–33. doi:https://doi.org/10.1002/jmv.25587.
- Lee AJ, Ashkar AA. The dual nature of type I and type II interferons. Front Immunol. 2018;9:2061. doi:https://doi.org/10.3389/fimmu.2018.02061.
- Hijano DR, Vu LD, Kauvar LM, et al. Role of type I interferon (IFN) in the respiratory syncytial virus (RSV) immune response and disease severity. Front Immunol. 2019;10:1–14. doi:https://doi.org/10.3389/fimmu.2019.00566.
- Aberle JH, Aberle SW, Rebhandl W, et al. Decreased interferon-gamma response in respiratory syncytial virus compared to other respiratory viral infections in infants. Clin Exp Immunol. 2004;137(1):146–150. doi:https://doi.org/10.1111/j.1365-2249.2004.02504.x.
- Jans J, Unger WWJ, Vissers M, et al. Siglec-1 inhibits RSV-induced interferon gamma production by adult T cells in contrast to newborn T cells. Eur J Immunol. 2018;48(4):621–631. doi:https://doi.org/10.1002/eji.201747161.